A meta-analysis aggregating 21 CAR-T cell therapy clinical trials reports very high cytokine release syndrome incidence alongside low treatment-related mortality. The analysis estimates cytokine release syndrome in 77.6% of patients, with treatment-related mortality at 4.6% across included studies. The findings frame CAR-T toxicities in quantitative terms for clinicians balancing efficacy and risk, while also reinforcing that hemodynamic inflammatory complications remain common even as fatal outcomes are relatively infrequent. The study also provides a baseline dataset for future head-to-head comparisons of toxicity mitigation strategies and patient selection approaches. For product developers and trial designers, the meta-analytic separation of CRS frequency and fatality supports clearer endpoint selection beyond mortality alone—particularly when therapies evolve and supportive care changes over time.
Get the Daily Brief